Teacher Retirement System of Texas Makes New $276,000 Investment in NewAmsterdam Pharma (NASDAQ:NAMS)

Teacher Retirement System of Texas acquired a new stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,753 shares of the company’s stock, valued at approximately $276,000.

Several other large investors have also recently made changes to their positions in the company. FMR LLC boosted its stake in NewAmsterdam Pharma by 35.6% during the third quarter. FMR LLC now owns 330,412 shares of the company’s stock valued at $5,485,000 after buying an additional 86,712 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of NewAmsterdam Pharma by 1,231.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 239,283 shares of the company’s stock worth $3,972,000 after acquiring an additional 221,305 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of NewAmsterdam Pharma by 176.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company’s stock valued at $371,000 after acquiring an additional 14,280 shares during the last quarter. State Street Corp grew its holdings in shares of NewAmsterdam Pharma by 168.7% in the third quarter. State Street Corp now owns 37,915 shares of the company’s stock valued at $629,000 after purchasing an additional 23,805 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in NewAmsterdam Pharma by 1.6% in the third quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock worth $1,433,000 after purchasing an additional 1,399 shares during the last quarter. 89.89% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $40.00 price objective on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. HC Wainwright reaffirmed a “buy” rating and issued a $48.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Needham & Company LLC dropped their price target on NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating for the company in a research report on Thursday, February 27th. UBS Group set a $41.00 price objective on NewAmsterdam Pharma in a research report on Monday, March 3rd. Finally, Scotiabank raised their price objective on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a research note on Thursday, February 27th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $43.33.

Insider Buying and Selling

In related news, Director James N. Topper purchased 4,005 shares of NewAmsterdam Pharma stock in a transaction that occurred on Tuesday, March 4th. The shares were bought at an average price of $21.02 per share, with a total value of $84,185.10. Following the purchase, the director now directly owns 3,012,434 shares of the company’s stock, valued at approximately $63,321,362.68. This represents a 0.13 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Louise Frederika Kooij sold 150,000 shares of the business’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the completion of the sale, the chief accounting officer now directly owns 15,000 shares of the company’s stock, valued at approximately $305,550. This trade represents a 90.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 19.50% of the stock is owned by corporate insiders.

NewAmsterdam Pharma Trading Down 10.2 %

NAMS stock opened at $18.38 on Wednesday. The stock has a market cap of $2.02 billion, a PE ratio of -7.07 and a beta of -0.04. NewAmsterdam Pharma has a 12 month low of $15.19 and a 12 month high of $27.29. The company has a 50-day moving average price of $21.50 and a 200 day moving average price of $21.32.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The business had revenue of $12.77 million for the quarter, compared to analyst estimates of $3.30 million. Sell-side analysts forecast that NewAmsterdam Pharma will post -1.75 EPS for the current year.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.